JP2014521675A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521675A5
JP2014521675A5 JP2014523289A JP2014523289A JP2014521675A5 JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5 JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014523289 A JP2014523289 A JP 2014523289A JP 2014521675 A5 JP2014521675 A5 JP 2014521675A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
biotinylated
group
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523289A
Other languages
English (en)
Japanese (ja)
Other versions
JP6019118B2 (ja
JP2014521675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064576 external-priority patent/WO2013017494A1/en
Publication of JP2014521675A publication Critical patent/JP2014521675A/ja
Publication of JP2014521675A5 publication Critical patent/JP2014521675A5/ja
Application granted granted Critical
Publication of JP6019118B2 publication Critical patent/JP6019118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523289A 2011-08-02 2012-07-25 吸入に適した酸化型アビジンの医薬品組成物 Active JP6019118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006338 2011-08-02
EP11006338.5 2011-08-02
PCT/EP2012/064576 WO2013017494A1 (en) 2011-08-02 2012-07-25 Pharmaceutical composition of oxidised avidin suitable for inhalation

Publications (3)

Publication Number Publication Date
JP2014521675A JP2014521675A (ja) 2014-08-28
JP2014521675A5 true JP2014521675A5 (cg-RX-API-DMAC7.html) 2015-08-27
JP6019118B2 JP6019118B2 (ja) 2016-11-02

Family

ID=46581966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523289A Active JP6019118B2 (ja) 2011-08-02 2012-07-25 吸入に適した酸化型アビジンの医薬品組成物

Country Status (19)

Country Link
US (1) US9872831B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739314B1 (cg-RX-API-DMAC7.html)
JP (1) JP6019118B2 (cg-RX-API-DMAC7.html)
KR (1) KR101966630B1 (cg-RX-API-DMAC7.html)
CN (1) CN103717239B (cg-RX-API-DMAC7.html)
AU (1) AU2012292229B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014002593B1 (cg-RX-API-DMAC7.html)
CA (1) CA2842276C (cg-RX-API-DMAC7.html)
DK (1) DK2739314T3 (cg-RX-API-DMAC7.html)
EA (1) EA026453B1 (cg-RX-API-DMAC7.html)
ES (1) ES2729549T3 (cg-RX-API-DMAC7.html)
IL (1) IL230597A0 (cg-RX-API-DMAC7.html)
MX (1) MX355177B (cg-RX-API-DMAC7.html)
PH (1) PH12014500193A1 (cg-RX-API-DMAC7.html)
PL (1) PL2739314T3 (cg-RX-API-DMAC7.html)
PT (1) PT2739314T (cg-RX-API-DMAC7.html)
UA (1) UA114482C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013017494A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401921B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941243A4 (en) 2013-01-04 2016-09-14 Massachusetts Inst Technology SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE
EP3458097A4 (en) * 2016-05-19 2020-01-08 University of Miami TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
WO1995003034A1 (en) 1993-07-19 1995-02-02 Amgen Inc. Stabilization of aerosolized proteins
DE69830305T2 (de) * 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
EP1169053A1 (en) * 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ITRM20030196A1 (it) * 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
BRPI0517204A (pt) * 2004-12-17 2008-09-30 Cipla Ltd sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US8562947B2 (en) * 2007-08-02 2013-10-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oxidized avidin with high residency time in the treated tissues
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof

Similar Documents

Publication Publication Date Title
US10550118B2 (en) JAK inhibitors containing a 4-membered heterocyclic amide
US12398135B2 (en) Dimethyl amino azetidine amides as JAK inhibitors
KR102568333B1 (ko) Jak 저해제 화합물을 사용하는 치료 방법
ES2391087T3 (es) Anticuerpos de IL-9 recombinantes y usos de los mismos
HRP20210650T1 (hr) Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
Maijenburg et al. Mesenchymal stromal cell migration: possibilities to improve cellular therapy
JP2018109052A5 (cg-RX-API-DMAC7.html)
JP2025023916A5 (cg-RX-API-DMAC7.html)
JP2011173911A5 (cg-RX-API-DMAC7.html)
JP2009521909A5 (cg-RX-API-DMAC7.html)
JP2018009002A5 (cg-RX-API-DMAC7.html)
JP2010270136A (ja) 安定化した抗rsv抗体液体製剤
JP2013121353A5 (cg-RX-API-DMAC7.html)
JP2011530536A5 (cg-RX-API-DMAC7.html)
JP2014521675A5 (cg-RX-API-DMAC7.html)
Merolla et al. Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta.
JP2019537617A5 (cg-RX-API-DMAC7.html)
CN104231080A (zh) 全人源抗人白介素17a单链抗体
JP2010538619A5 (cg-RX-API-DMAC7.html)
JP2021504321A5 (cg-RX-API-DMAC7.html)
Zgair Escherichia coli flagellin stimulates pro-inflammatory immune response
JP2013525310A5 (cg-RX-API-DMAC7.html)
US20230201208A1 (en) Composition and methods for treating respiratory diseases
ES2729549T3 (es) Composición farmacéutica de avidina oxidada adecuada para la inhalación
JPWO2022125523A5 (cg-RX-API-DMAC7.html)